Frankfurt
11.09.26 | 08:09
0,049 Euro
-2,38 % -0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Klaria Pharma Holding AB: Klaria and RTHS enter collaboration agreement for the development of early migraine detection and treatment | 87 | GlobeNewswire (Europe) | Klaria AB and Gothenburg-based RTHS have entered a collaboration agreement that aims to exploit RTHS sensor-based blood dynamics measurements to detect migraine prior to symptoms appearing in patients.... ► Artikel lesen | |
| 01.09. | Klaria Pharma Holding AB: Klaria Interim Report Q2 2026 | 125 | GlobeNewswire (Europe) | Summary of interim reportSecond quarter of 2026
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for the quarter amounted to 4.4 MSEK... ► Artikel lesen | |
| 01.09. | Summons to extraordinary general meeting of Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 01.09. | Klaria Pharma Holding AB (publ) calls an Extraordinary General Meeting to resolve on a Rights Issue of units and an amendment of the Articles of Association | 1 | Cision News | ||
| 01.09. | Klaria Pharma Holding AB Q2 Loss Narrows | 1 | RTTNews | ||
| 26.08. | KLARIA PHARMA HOLDING AB: Klaria reschedules quarterly report date | 1 | Cision News | ||
| 07.08. | Klaria Pharma Holding AB: Klaria Receives EU Notification of Allowance for Sumatriptan Alginate Film | 647 | GlobeNewswire (Europe) | Klaria has received a Notice of Allowance from the European Patent Office for the second patent in the Sumatriptan Alginate Film (SAF) patent portfolio. The Notice of Allowance indicates that the second... ► Artikel lesen | |
| 26.06. | Klaria Pharma Holding AB: Report from the Annual General Meeting of Klaria Pharma Holding AB (publ) | 411 | GlobeNewswire (Europe) | Today, the Annual General Meeting 2026 of Klaria Pharma Holding AB (publ), reg. no. 556959-2917, was held. Below is a summary of the resolutions adopted by the Annual General Meeting (all in accordance... ► Artikel lesen | |
| KLARIA PHARMA Aktie jetzt für 0€ handeln | |||||
| 05.06. | KLARIA PHARMA HOLDING AB: Klaria Annual Report 2025 | 1 | Cision News | ||
| 05.06. | Klaria Pharma Holding AB: Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK | 219 | GlobeNewswire (Europe) | Klaria Pharma Holding AB (publ) ("Klaria" or the "Company") announces that Klaria has entered into an agreement for a bridge loan of 25 MSEK from a Swedish finance company. The agreement also includes... ► Artikel lesen | |
| 29.05. | Klaria Pharma Holding AB: Klaria Interim Report Q1 2026 | 224 | GlobeNewswire (Europe) | Klaria Interim Report Q1 2026 1 January - 31 March
Summary of the interim reportFirst quarter of 2026 The group in total - Net sales 0.1 MSEK (9.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D... ► Artikel lesen | |
| 28.05. | KLARIA PHARMA HOLDING AB: Klaria adjusts annual report release date | 1 | Cision News | ||
| 25.05. | Klaria Pharma Holding AB: Summons to the Annual General Meeting of Klaria Pharma Holding AB (publ) | 370 | GlobeNewswire (Europe) | With a change from what has been previously announced, the shareholders of Klaria Pharma Holding AB (publ), corporate registration number 556959-2917, are hereby invited to attend the Annual General... ► Artikel lesen | |
| 22.05. | KLARIA PHARMA HOLDING AB: Klaria postpones interim Q1 report | 1 | Cision News | ||
| 21.05. | KLARIA PHARMA HOLDING AB: Klaria postpones publication of the annual report | 2 | Cision News | ||
| 23.04. | Notice of the Annual General Meeting of Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 05.04. | KLARIA PHARMA HOLDING AB: Annula Genernal Meeting Date Change: Klaria Pharma Holding (publ) | 2 | Cision News | ||
| 19.03. | Correction: Incorrect inclusion of MAR text in earlier release.Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 1 | Cision News | ||
| 19.03. | Klaria Pharma Holding AB: Summary of extraordinary general meeting in Klaria Pharma Holding AB (publ) | 384 | GlobeNewswire (Europe) | Today, an extraordinary general meeting was held in Klaria Pharma Holding AB (publ), company registration number 556959-2917. Below is a summary of the resolutions adopted by the extra general meeting... ► Artikel lesen | |
| 20.02. | Klaria Pharma Holding AB: Klaria Year-End Report | 777 | GlobeNewswire (Europe) | Klaria Year-End Report Q4 2025
1 January-31 December 2025
SummaryFourth quarter of 2025 The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.0 MSEK)
- R&D expenses for... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRISTOL-MYERS SQUIBB | 54,76 | -0,31 % | Bristol-Myers Squibb Company: National Coalition of Pharmaceutical Industry, Academic, and Nonprofit Partners Launches Fifth Winn CIPP Cohort | NORTHAMPTON, MA / ACCESS Newswire / September 9, 2026 / Organizations Across Sectors Unite Through the Winn Awards to Advance Better Science For All Previously published by the Robert A. Winn Excellence... ► Artikel lesen | |
| DERMAPHARM | 37,400 | -2,35 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| INCYTE | 104,60 | -1,55 % | Cantor Fitzgerald reiterates Neutral on Incyte stock after conference | ||
| GREEN THUMB INDUSTRIES | 6,420 | -1,08 % | Green Thumb Industries Has Hit a Rough Patch. Here's Why Its Best Days Could Be Ahead. | ||
| SELLAS LIFE SCIENCES | 10,000 | -14,16 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| COSMO | 57,70 | -0,52 % | Nach Abnehmspritzen: Dieser Milliarden-Boom steht in den Startlöchern | © Foto: DALL·ESeit Jahrzehnten gibt es kaum neue Mittel gegen erblichen Haarausfall. Jetzt stehen mehrere Wirkstoffe vor dem Durchbruch - und Anleger entdecken einen gewaltigen Selbstzahlermarkt Enthaltene... ► Artikel lesen | |
| OPKO HEALTH | 1,270 | +3,25 % | OPKO Health: Strategiewechsel hin zu Therapeutika, gestützt durch hohe Liquidität | ||
| OXFORD BIOMEDICA | 4,900 | 0,00 % | Oxford Biomedica PLC - Holding(s) in Company | ||
| CITIUS PHARMACEUTICALS | 0,584 | -0,15 % | Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update | $7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®
$17 million in cash and cash equivalents as of June 30, 2026
Expanded... ► Artikel lesen | |
| SUMITOMO PHARMA | 8,593 | +1,36 % | Sumitomo Pharma, Novo Nordisk Win Japan Nod For Wegovy In MASH | TOKYO (dpa-AFX) - Sumitomo Pharma Co., Ltd. (4506.T) announced on Friday that Japan has cleared Wegovy Subcutaneous Injection, which it co-promotes with Novo Nordisk B A/S (NVO), to treat metabolic... ► Artikel lesen | |
| VETOQUINOL | 76,60 | 0,00 % | Vetoquinol: 2026 Half Year Results | Sales: €259 million (+3.4% at constant exchange rates and +0.7% on a reported basis)
Essential Products sales: €169 million (+3.7% at constant exchange rates and +2.2% on a reported basis)
EBIT... ► Artikel lesen | |
| ASTRID INTELLIGENCE | 0,001 | 0,00 % | Astrid Intelligence - Corrective announcement - Directors' Dealing | ||
| BIOHARVEST SCIENCES | 1,440 | +5,11 % | BioHarvest Sciences Inc.: BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update | Secured first ever CDMO Manufacturing Agreement supporting planned 20-ton commercial production program over two years for rare botanical fragrance, that BioHarvest expects to drive profitable growth... ► Artikel lesen | |
| OCUMENSION THERAPEUTICS | 0,565 | -1,74 % | OCUMENSION-B OT-301 New Drug Application for Lowering Intraocular Pressure Accepted | ||
| BAYER | 48,170 | -1,09 % | Nicht nur Bayer verdient am Weltmarkt mit, ohne überall selbst präsent zu sein: Ein australischer Psychedelika-Anbieter setzt auf dasselbe Grundprinzip |
Das Unternehmen KLARIA PHARMA HOLDING AB kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,049 Euro und damit -2,38 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KLARIA PHARMA HOLDING AB finden Sie auf Wallstreet Online.